TY  - JOUR
AU  - Spelman, Tim
AU  - Kalincik, Tomas
AU  - Jokubaitis, Vilija
AU  - Zhang, Annie
AU  - Pellegrini, Fabio
AU  - Wiendl, Heinz
AU  - Belachew, Shibeshih
AU  - Hyde, Robert
AU  - Verheul, Freek
AU  - Lugaresi, Alessandra
AU  - Havrdova, Eva
AU  - Horakova, Dana
AU  - Grammond, Pierre
AU  - Duquette, Pierre
AU  - Prat, Alexandre
AU  - Iuliano, Gerardo
AU  - Terzi, Murat
AU  - Izquierdo, Guillermo
AU  - Hupperts, Raymond M. M.
AU  - Boz, Cavit
AU  - Pucci, Eugenio
AU  - Giuliani, Giorgio
AU  - Sola, Patrizia
AU  - Spitaleri, Daniele L. A.
AU  - Lechner-Scott, Jeannette
AU  - Bergamaschi, Roberto
AU  - Grand'Maison, Francois
AU  - Granella, Franco
AU  - Kappos, Ludwig
AU  - Trojano, Maria
AU  - Butzkueven, Helmut
AU  - MSBase Investigators TOP Investiga
PY  - 2016
DO  - 10.1212/CPJ.0000000000000227
SN  - 2163-0402
UR  - http://hdl.handle.net/10668/19139
T2  - Neurology-clinical practice
AB  - Background: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS) initiating natalizumab compared with interferon-beta (IFN-beta)/glatiramer acetate (GA) therapies, using...
LA  - en
PB  - Lippincott williams & wilkins
KW  - Remitting multiple-sclerosis
KW  - Long-term safety
KW  - Patient selection
KW  - Disease-activity
KW  - Interferon-beta
KW  - Double-blind
KW  - Predictors
KW  - Benefits
KW  - Outcomes
KW  - Risk
TI  - Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS
TY  - research article
VL  - 6
ER  -